BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 19076348)

  • 1. RANK/RANKL: regulators of immune responses and bone physiology.
    Leibbrandt A; Penninger JM
    Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANK(L) as a key target for controlling bone loss.
    Leibbrandt A; Penninger JM
    Adv Exp Med Biol; 2009; 647():130-45. PubMed ID: 19760071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.
    Leibbrandt A; Penninger JM
    Adv Exp Med Biol; 2009; 649():100-13. PubMed ID: 19731623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.
    Pivonka P; Zimak J; Smith DW; Gardiner BS; Dunstan CR; Sims NA; Martin TJ; Mundy GR
    J Theor Biol; 2010 Jan; 262(2):306-16. PubMed ID: 19782692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPG, RANK and RANK ligand expression in thyroid lesions.
    Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
    Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
    Kobayashi Y; Takahashi N
    Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.